Eleva’s Factor H (CPV-104) program to enter clinic in 2025 in C3G, with dry AMD identified as potential second indication
FREIBURG IM BREISGAU, Germany, February 20, 2025 / Biotech Newswire / -- Eleva, a pioneer in unlocking difficult-to-produce biologics based on a breakthrough moss-based platform, announced today the appointment of Dr. Martin Bauer, MD, as new Chief Medical Officer. His appointment reflects the growing maturity of Eleva’s proprietary pipeline, which includes Eleva’s Factor H (CPV-104) program, a novel complement regulator with therapeutic potential in several indications, and aGal (RPV-001), a best-in-class approach to treat Fabry disease.
Martin Bauer joins Eleva with over two decades of clinical development expertise, having held various management positions of increasing responsibility. His roles include senior and leadership positions at Atriva Therapeutics, Merck, Basilea, Otsuka, ICON, and Boehringer Ingelheim. He is board-certified in Anesthesiology, Rescue Medicine, and Medical Informatics, and has over 10 years of experience working in academic hospitals. Martin Bauer earned his MD from Julius-Maximilians University of Würzburg, Germany.
“With the clinical trial start for our second fully owned drug development program on the horizon, we have decided to appoint an experienced Chief Medical Officer orchestrating all of these activities,” commented Björn Cochlovius Ph.D., Chief Executive Officer of Eleva. “Martin’s deep expertise in clinical development across several indications and modalities will be very valuable for Eleva’s continued growth as a drug development organization.”
Commenting on his appointment, Martin Bauer added: “I’m thrilled to support Eleva as the company further strengthens its drug development activities with additional pipeline programs and potentially new indications being explored. Our Factor H program in particular has the potential to unlock a novel therapeutic mode-of-action that is clearly differentiated from the standard-of-care.”
For high resolution please click the image.
+++ Meet the Eleva team during BIO-Europe Spring in Milan, Italy, March 17-19, 2025, to learn more about future collaboration and investment opportunities +++
ABOUT ELEVA
Eleva is a clinical-stage biopharmaceutical company unlocking difficult-to-produce biologics based on a breakthrough technology platform. The company’s proprietary drug development activities currently focus on complement disorders and enzyme replacement therapies. Factor H (CPV-104), a recombinant version of human complement Factor H, is expected to enter clinical studies in C3 Glomerulopathy (C3G) in H1 2025. The company’s aGal (RPV-001) program to treat Fabry disease has completed a Phase 1b clinical study with promising results. All programs are sourced from Eleva’s transformative moss-based expression system, which allows lab to GMP-scale manufacturing of challenging proteins with previously untapped therapeutic potential.
Contacts
Eleva
Fabienne Zeitter
Director Marketing
This email address is being protected from spambots. You need JavaScript enabled to view it.
+49 761 470 99 0
Valency Communications
Mario Brkulj
This email address is being protected from spambots. You need JavaScript enabled to view it.
+49 160 9352 9951
Keywords: Appointments and Schedules; Moss-based expression system; Biologics manufacturing; Biological Products; Complement Factor H; Macular Degeneration; Eleva; Martin Bauer; Factor H (CPV-104); C3 Glomerulopathy (C3G); Dry AMD; aGal (RPV-001); Fabry disease; Complement regulator; Drug development; Clinical development; Enzyme replacement therapy; GMP-scale manufacturing; BIO-Europe Spring; Björn Cochlovius
Source: Biotech Newswire